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Background: Postoperative nausea and vomiting (PONV) is a common complication after 
surgery, which increases physical and psychological discomfort and delays recovery. The aim 
of this study was to test the hypothesis that ramosetron is comparable to ondansetron for the 
treatment of established PONV after laparoscopic surgery using a prospective, randomized, 
double-blinded, noninferiority study.
Methods: Patients who had at least two risk factors of PONV and underwent laparoscopic 
surgery under general anesthesia were assessed for eligibility. Patients who developed PONV 
within the first 2 h after anesthesia received ondansetron (4 mg) or ramosetron (0.3 mg) intra-
venously in a randomized double-blind manner. Patients were then observed for 24 h after drug 
administration. The incidence of nausea and vomiting, severity of nausea, rescue antiemetic 
necessity, and adverse effects at 0–2 or 2–24 h after drug administration was evaluated. The 
primary endpoint was the rate of patients exhibiting a complete response, defined as no emesis 
and no further rescue antiemetic medication for 24 h after drug administration.
Results: Among the 583 patients, 210 (36.0%) developed PONV and were randomized to 
either the ondansetron (n=105) or ramosetron (n=105) group. Patient’s characteristics were 
similar between the groups. The complete response rate was 44.1% in the ondansetron group 
and 52.9% in the ramosetron group after 24 h of initial antiemetic administration. The incidence 
of adverse events was not different between the groups.
Conclusion: We found evidence to support the noninferiority of ramosetron (0.3 mg) compared 
to ondansetron (4 mg) for the treatment of established PONV in moderate to high-risk patients 
undergoing laparoscopic surgery.
Keywords: laparoscopic surgery, ondansetron, postoperative nausea and vomiting, ramosetron, 
non-inferiority, antiemetic
Introduction
Despite considerable effort in evaluating antiemetic strategies and the development of 
a new antiemetic class, postoperative nausea and vomiting (PONV) remains one of the 
most common and distressing complications after surgery. PONV not only increases 
physical and psychological discomfort but also causes wound dehiscence, dehydra-
tion, and electrolyte imbalance, which leads to delayed recovery, prolonged hospital 
stays, and life-threatening aspiration.1,2 Published evidence suggests that prophylactic 
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administration of antiemetic drugs should be considered for 
patients with two or more PONV risk factors, such as the 
female gender, nonsmoking, and the use of postoperative 
opioids.3,4 In addition, various approaches to prevent or treat 
PONV have been studied, especially for high-risk patients, 
which contribute to early recovery, increased patient satisfac-
tion, and reduced side effects.
Among the  current ly  avai lable  ant iemet ics , 
5-hydroxytryptamine receptor 3 (5-HT
3
) antagonists are 
frequently used for prophylaxis against PONV and treat-
ment of established PONV. Ramosetron is a newly devel-
oped selective 5-HT
3
 receptor antagonist with longer action 
duration (up to 48 h) and higher receptor affinity than its 
previously developed congeners, including ondansetron.5–7 
Ondansetron is an effective prophylactic and therapeutic 
5-HT
3
 receptor antagonist for the treatment of PONV.8–10 
Although ramosetron is superior to ondansetron for prevent-
ing PONV, ramosetron and ondansetron have never been 
compared with respect to their therapeutic efficacy in treating 
established PONV.
Therefore, we designed a randomized controlled trial to 
compare the therapeutic efficacy of ramosetron and ondanse-
tron for the treatment of established PONV in patients 
following laparoscopic surgery under general anesthesia.
Methods
After obtaining approval from the institutional review boards 
of Yonsei University Severance Hospital, Seoul National 
University Bundang Hospital, and Ewha Womans University 
Mokdong Hospital, a total 610 patients undergoing laparo-
scopic surgery between July 2015 and September 2016 were 
assessed for eligibility. An independent institutional review 
board from all the institutions at which the participating 
anesthesiologists are affiliated has approved this study. This 
study was registered at http://ClinicalTrials.gov (registration 
number NCT03017222).
Written informed consent was obtained from all patients 
before they were recruited. Patient inclusion criteria were 
as follows: age 19–65 years, undergoing elective laparo-
scopic surgery under inhalation anesthesia, surgery duration 
between 30 min and 4 h, American Society of Anesthe-
siologists physical status I or II, and at least two of these 
risk factors: female gender, history of motion sickness or 
PONV, nonsmoking, and postoperative opioid use. Patient 
exclusion criteria were as follows: history of being allergic 
to 5-HT
3
 receptor antagonists, anticancer chemotherapy 
history, chronic opioid use, alcohol abuse, drug abuse, admin-
istration of antiemetic medication within 24 h of surgery, 
steroids 24 h before or after surgery, presence of renal 
(serum Cr .1.6 mg/dL) or hepatic (liver enzymes more than 
twice the normal value) insufficiency, conversion to open 
laparotomy, pregnant, breastfeeding, borderline QTc prolon-
gation (.430 ms for male, .450 ms for female), and unable 
to understand pain scoring or express the PONV degree.
intraoperative and postoperative 
management
The anesthetic techniques were controlled at all three institu-
tions. Premedication was not administered. Anesthesia was 
induced using propofol (1.5–2 mg/kg) and fentanyl (1 µg/kg) 
or remifentanil (0.5–1 µg/kg/min) under standard monitoring; 
rocuronium (0.6 mg/kg) was administered to facilitate 
tracheal intubation. The patient’s lungs were ventilated with 
a tidal volume of 8 mL/kg of ideal body weight in 50% 
oxygen with air. Respiratory rate was adjusted to maintain 
an end-tidal CO
2
 pressure of 35–45 mmHg. Anesthesia was 
maintained with sevoflurane or desflurane and remifentanil 
(0.1–0.3 µg/kg/min). For management of postoperative pain, a 
single bolus dose of fentanyl (1 µg/kg) was administered intra-
venously 15 min before the end of surgery, and remifentanil 
intravenous infusion was stopped. Fentanyl (15–20 µg/kg at 
2 mL/h, 0.5 mL bolus, 15 min lock-out time, total 100 mL) 
was used in intravenous patient-controlled analgesia (PCA) 
pumps if indicated to control acute postoperative pain.
After extubation and transfer to the postanesthesia care 
unit (PACU), the patients were monitored with routine care 
and supplementary oxygen through a face mask. During 
PACU care, if patients developed nausea with numerical 
rating scale (NRS) $4 or vomiting within 2 h postopera-
tively, the therapeutic intervention designed to treat PONV 
ensued. The patients were randomly allocated into one of the 
two groups: the ondansetron group (Zofran® 4 mg) or ramose-
tron group (Nasea® 0.3 mg), using computer-generated ran-
dom number codes. When nausea of NRS $4 or vomiting 
still existed, metoclopramide (10 mg) as additional rescue 
antiemetic was administered and recorded. If PONV did 
not develop within 2 h postoperatively, we excluded the 
patient from study enrollment and administered prophylactic 
antiemetic agents, given the presence of the relevant risk 
factors for PONV. The study drugs were prepared in identical 
syringes and administered by the personnel who were not 
involved in this study. All patients, physicians, and investiga-
tors collecting data were blinded to group assignments.
Outcomes
The primary outcome variable was a complete response rate, 
defined as no retching and/or vomiting and no secondary 
rescue antiemetic administration. The secondary outcome 
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variables were incidence and severity of nausea, incidence 
of retching and/or vomiting, need for additional antiemetics, 
pain score, and requirements of rescue analgesics. The 
intensity of nausea was graded on an NRS using an 11-point 
scale, with 0=no nausea to 10=worst possible nausea. The 
severity of nausea was determined according to NRS scores: 
mild (1–3), moderate (4–6), and severe (7–10). Pain inten-
sity scores were measured on a visual analog scale (VAS) 
that ranged from 0 mm (no pain) to 100 mm (worst pain 
imaginable). The investigator blinded to group allocation 
evaluated incidence and severity of nausea, retching and/or 
vomiting, need for additional antiemetics, pain intensity, 
rescue analgesic, and adverse events for 24 h after administra-
tion of the study drug, which was divided into two intervals: 
0–2 h and 2–24 h.
statistical analysis
Statistical analyses were performed using SAS version 9.4 
(SAS Institute Inc., Cary, NC, USA). This study was per-
formed as a non-inferiority trial, designating ondansetron, the 
commonly used drug for treating PONV, as the comparison 
for the effects of ramosetron toward established PONV. 
A previous study demonstrated a complete response rate 
of 45% with ondansetron (4 mg) treatment for established 
PONV.9 As there was no previous study regarding ramosetron 
treatment for established PONV, a complete response rate was 
assumed as 55% and defined the margin of non-inferiority at 
an absolute risk difference of 10%. Therefore, we calculated 
that a study with 95 patients per group would have at least 
80% power, with one-sided type I error of 0.025, using a non-
inferiority test. Taking into consideration a 10% dropout rate, 
we decided to enroll 105 patients in each group. Categorical 
variables were analyzed using chi-square test or Fisher’s 
exact test and shown as number and percentage. Continuous 
variables were expressed as mean ± standard deviation or 
median [interquartile range] according to the normality, using 
Student’s t-test or Mann–Whitney U-test, as appropriate. 
P-values of ,0.05 were considered significant.
Results
A total of 610 patients were assessed for eligibility; 210 of 
the 583 patients observed for 2 h postoperatively at PACU 
were enrolled in this study and were randomly assigned to 
two treatment groups (Figure 1). After randomization, one 
patient withdrew consent, and three patients were excluded 
from the final analysis due to use of prohibited drugs without 
notification to the investigator; the remaining 206 patients 
completed the study. The baseline characteristics, including 
history of PONV or motion sickness, anesthetic, operative, 
and postoperative data, were similar between the groups 
(Table 1). Fentanyl-based intravenous PCA was used in 
62.6% of all patients. Although there was a higher trend of 
intravenous PCA use in the ondansetron group, it was not 
statistically significant (P=0.08). The number of patients 
Figure 1 Flow diagram of the study.
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$OORFDWLRQ
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1RWPHHWLQJLQFOXVLRQH[FOXVLRQFULWHULDQ 1RWGHYHORS3219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with $3 risk factors for PONV was 92 (90.2%) patients 
in the ondansetron group and 93 (89.4%) patients in the 
ramosetron group.
Our primary outcome was ramosetron noninferiority 
in comparison with ondansetron based on the complete 
response rate for 24 h after administration of the study drug. 
The complete response rate was 44.1% (45 of 102 patients) 
and 52.9% (55 of 104 patients) in the ondansetron and 
ramosetron group, respectively, for 24 h after administration 
of the study drug (absolute difference 8.8%, 95% CI -4.8 
to -22.4) (Figure 2). The incidence and severity of nausea 
were similar between the two groups during the study 
period (Table 2). No differences were observed between 
the groups with respect to the incidence of retching and/or 
vomiting during the study period. The overall incidence of 
PONV during 24 h after administration of the study drug 
was 83 (81.4%) in the ondansetron group and 78 (75.0%) in 
the ramosetron group.
No patient withdrew from the study due to adverse events. 
There were no differences in the incidences of headache, diz-
ziness, or drowsiness between the groups (Table 3). There 
were no significant differences with regard to the postop-
erative pain intensity and the rescue analgesic requirement 
during the study period (Table 4).
Discussion
In this prospective, randomized, double-blinded multicenter 
trial, we compared the therapeutic efficacy of a single dose of 
ramosetron (0.3 mg) with that of a single dose of ondansetron 
(4 mg) in the treatment of established PONV in a moderate 
to high-risk population undergoing laparoscopic surgery 
Table 1 Patient’s characteristics
Ondansetron 
group 
(n=102)
Ramosetron 
group 
(n=104)
P-value
age (years) 42.6±10.9 43.7±11.9 0.50
Women 97 (95.1) 96 (92.3) 0.41
Body mass index (kg/m2) 23.4±4.0 23.2±3.1 0.58
asa physical status 0.44
1 83 (81.4) 79 (76.0)
2 20 (19.6) 25 (24.0)
history of POnV or motion 
sickness 
38 (37.3) 42 (40.4) 0.65
nonsmoking 99 (97.1) 100 (96.2) 1.00
Simplified risk score 0.78
2 10 (10.2) 11 (10.6)
3 57 (55.9) 59 (56.7)
4 35 (34.3) 34 (32.7)
Duration of anesthesia (min) 123.9±47.5 121.4±66.2 0.75
Duration of surgery (min) 94.1±45.2 92.2±64.6 0.81
Duration of PaCU stay (min) 67.2±24.4 70.6±25.6 0.32
Use of fentanyl-based iV PCa 70 (68.6) 59 (56.7) 0.08
Type of surgical procedure 0.35
Cholecystectomy 34 (33.3) 43 (41.3)
hysterectomy 21 (20.6) 18 (17.3)
Ovarian cystectomy 19 (18.6) 20 (19.2)
Myomectomy 19 (18.6) 13 (12.5)
salpingo-oophorectomy 6 (5.9) 8 (7.7)
Other gynecologic surgery 3 (2.9) 2 (1.9)
Note: Values are presented as mean ± standard deviation or number (%) of patients.
Abbreviations: asa, american society of anesthesiologists; POnV, postoperative 
nausea and vomiting; PaCU, postanesthesia care unit; iV PCa, intravenous patient-
controlled analgesia.
Figure 2 Complete response rate for 24 h after administration of the study drug.
5HWFKLQJYRPLWLQJRUUHVFXHDQWLHPHWLF
&RPSOHWHUHVSRQVH
2QGDQVHWURQJURXS 5DPRVHWURQJURXS
5HWFKLQJYRPLWLQJRUUHVFXHDQWLHPHWLF
&RPSOHWHUHVSRQVH
Table 2 incidence of nausea, retching/vomiting, and requirement 
for rescue antiemetic treatment
Ondansetron 
group 
(n=102)
Ramosetron 
group 
(n=104)
P-value
Patients with nausea 
0–2 h 70 (68.6) 64 (61.5) 0.29
2–24 h 59 (57.8) 57 (54.8) 0.66
0–24 h 83 (81.4) 77 (74.0) 0.21
nausea severity 
0–2 h (mild/
moderate/severe)
28/27/15 27/27/10 0.53
2–24 h (mild/
moderate/severe)
21/31/7 24/24/9 0.84
Patients with retching/vomiting 
0–2 h 10 (9.8) 15 (14.4) 0.31
2–24 h 14 (13.7) 16 (15.4) 0.74
0–24 h 22 (21.6) 27 (26.0) 0.46
Patients requiring rescue antiemetic 
0–2 h 27 (26.5) 20 (19.2) 0.22
2–24 h 27 (26.5) 23 (22.1) 0.47
0–24 h 46 (45.1) 39 (37.5) 0.27
Note: Values are presented as number (%) of patients.
Table 3 side effects of antiemetic drugs
Ondansetron 
group 
(n=102)
Ramosetron 
group 
(n=104)
P-value
headache 7 (6.9) 2 (1.9) 0.10
Dizziness 11 (10.8) 14 (13.5) 0.56
Drowsiness 15 (14.7) 17 (16.3) 0.75
Note: Values are presented as number (%) of patients.
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under general anesthesia. Noninferiority analysis revealed 
that ramosetron appears to be noninferior to ondansetron for 
the treatment of established PONV in this subset of patients 
for 24 h after administration of the study drug.
The etiology of PONV is multifactorial, with risk factors 
that include age, sex, obesity, a history of motion sickness 
or previous PONV, smoking habits, anesthetic technique, 
and postoperative use of opioids.11 Type of surgery as a 
risk factor is still debated; laparoscopic surgery is associ-
ated with a higher incidence of PONV when compared 
with open surgery due to CO
2
 insufflation, residual pneu-
moperitoneum, peritoneal distension, and diaphragm and 
visceral organ irritation.12 Several meta-analyses report that 
ondansetron is one of the most effective antiemetic agents 
available for prevention and treatment of PONV, suggesting 
that intravenous ondansetron 4 mg was the optimal dose for 
treating established PONV.9,13 However, little information 
exits on the therapeutic efficacy of a newly developed 5-HT
3
 
receptor antagonist in patients with established PONV after 
laparoscopic surgery. In this study, we compared the clinical 
evidence for therapeutic response to ramosetron with that 
of ondansetron for established PONV treatment. There was 
no statistically significant difference between ramosetron 
and ondansetron as a treatment for established PONV after 
laparoscopic surgery in moderate to high-risk patients for 
24 h after administration of the study drug.
In a recent meta-analysis comparing ramosetron to 
ondansetron for preventing PONV during various types of 
surgery, there was no difference in incidence of nausea, need 
for rescue antiemetics, and incidence of side effects, but there 
was significantly less vomiting in patients receiving ramose-
tron during early (0–6 h) and late (6–24 h) time periods.14–16 
In this study, we had expected that ramosetron would have an 
advantage over ondansetron in treating vomiting or prevent-
ing further retching or vomiting in the late period because 
differences exist in receptor affinity, pharmacokinetics, and 
the half-life between ramosetron and ondansetron (9 vs 3.5 h, 
respectively).17 Although differences did not reach statistical 
significance, 53% of patients receiving ramosetron treatment 
were prevented from further retching or vomiting without 
secondary rescue antiemetic administration compared to 
44% of patients receiving ondansetron treatment. The current 
findings with ondansetron (4 mg) are consistent with previous 
results evaluating ondansetron use for treating established 
PONV; the complete response rate at 24 h after ondansetron 
administration was 45%–47%.9,18
The incidence of PONV increases exponentially from 
10% when no risk factors are present to 78% when all four 
risk factors are present,3 and identified risk factors include 
female gender, nonsmoking, the use of postoperative opioids, 
and prior history of motion sickness or PONV. The present 
study was designed to evaluate the therapeutic efficacy of 
ramosetron and ondansetron in patients at moderate to high 
risk of PONV, and thus we planned to include patients with 
two or more risk factors. However, after randomization and 
treatment allocation, we found that 90% of the enrolled 
patients had at least three risk factors, making our study unin-
tentionally focused on high-risk patients. This may be due to 
the fact that the present study was done on the “treatment” 
of established PONV rather than its prevention, and theoreti-
cally, treatment studies are usually more difficult to perform. 
For instance, if a baseline risk of 40% PONV is expected, 
then of 100 patients who have given their informed consent 
to take part in a treatment trial, roughly 40 will eventually 
suffer from PONV symptoms and then be randomized and 
treated. The baseline risk for PONV after randomization 
could be increased compared to the general population, as 
patients with higher baseline risk of PONV would be more 
likely to develop PONV during the observation period for 
treatment decision. Although the 36% incidence of PONV 
during the first 2 h postrecovery of our study was found 
to rather accurately reflect common clinical practice,19 
the observed complete response rates after treatment for 
established PONV may have led to different results if the 
enrolled patients had been more evenly distributed in terms 
of risks for PONV. Future studies are needed to validate the 
therapeutic efficacy of ramosetron in patients at relatively 
low risk of PONV.
In this study, there were no differences in the incidence of 
adverse events such as headache, dizziness, and drowsiness 
between the groups. Excessive sedation and extrapyramidal 
symptoms also were not observed in any patients. VAS scores 
of postoperative pain and requirement of rescue analgesics 
were similar in both groups.
Our study had limitations. First, we compared two 
5-HT
3
 antagonists and did not use a placebo control group. 
However, given the high risk of PONV associated with 
Table 4 Pain intensity scores and requirement of rescue analgesic
Ondansetron 
group 
(n=102)
Ramosetron 
group 
(n=104)
P-value
Pain scores
0–2 h 54.3±19.7 51.5±20.5 0.32
2–24 h 32.5±15.9 34.9±16.8 0.30
Patients requiring rescue analgesic
0–2 h 72 (70.6) 74 (71.2) 0.93
2–24 h 49 (48.0) 54 (51.9) 0.58
Note: Values are presented as mean ± standard deviation or number (%) of patients.
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patient-related factors and surgery type, having a placebo 
arm was considered unethical. Valid data on the therapeutic 
efficacy and dose-response of other classic antiemetics are 
needed. Second, we observed therapeutic responses during 
24 h after administration of the study drug. Since the longer 
efficacy of ramosetron compared with ondansetron has been 
demonstrated, ramosetron could prevent further PONV 
development longer than 24 h after administration of the 
study drug.
Conclusion
We observed evidence to support the noninferiority of 
ramosetron (0.3 mg) compared to ondansetron (4 mg) for 
the treatment of established PONV in moderate to high-risk 
patients undergoing laparoscopic surgery.
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